USPTO Examiner CHASE CAROL ANN - Art Unit 1646

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18423752ANTIBODIES TO PROGRAMMED CELL DEATH PROTEIN 1 THAT ARE PD-1 AGONISTSJanuary 2024April 2024Allow300YesNo
18405977BINDING MOLECULESJanuary 2024August 2024Allow800YesNo
18077318Use of Amivantamab to Treat Colorectal CancerDecember 2022April 2025Abandon2820NoNo
18051833PHARMACEUTICAL COMPOSITION OF A HUMANIZED ANTI-CD40 ANTIBODYNovember 2022December 2024Allow2620YesNo
17615475A TETRAVALENT BISPECIFIC ANTIBODY AGAINST PD-1 AND PD-L1November 2021December 2024Allow3700YesNo
17612959ANTI-B7-H3 ANTIBODY AND METHODS OF USE THEREOFNovember 2021June 2025Allow4311NoNo
17503473EXTRACELLULAR VESICLE BIOMARKERS FOR ENDOMETRIAL CANCEROctober 2021January 2025Abandon3921NoNo
17475216TRISPECIFIC PROTEINS AND METHODS OF USESeptember 2021March 2025Allow4210YesNo
17447607DENDRITIC CELL ASGPR TARGETING IMMUNOTHERAPEUTICS FOR MULTIPLE SCLEROSISSeptember 2021August 2024Allow3511YesNo
17436204Anti-ICOS Antibodies for the Treatment of CancerSeptember 2021April 2025Abandon4310NoNo
17429580ANTIGEN BINDING MOLECULES AND EPITOPES, AND USES THEREOFAugust 2021November 2024Abandon3910NoNo
17427882ANTI-GITR ANTIGEN-BINDING DOMAINS AND USES THEREOFAugust 2021May 2025Abandon4601NoNo
17427625ANTI-PD-1 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND PHARMACEUTICAL USE THEREOFJuly 2021June 2025Allow4611YesNo
17386437NANOPARTICLE FORMULATIONSJuly 2021May 2025Allow4611YesNo
17424603NOVEL CANCER ANTIGENS AND ANTIBODIES OF SAID ANTIGENSJuly 2021January 2025Abandon4210NoNo
17413892IMMUNE EFFECTOR CELL TARGETING GPC3 AND APPLICATION THEREOFJune 2021February 2025Abandon4410NoNo
17346089METHODS OF EXPLOITING ONCOGENIC DRIVERS ALONG THE HUMAN CYCLIN G1 PATHWAY FOR CANCER GENE THERAPYJune 2021March 2025Abandon4510NoNo
17343150Daratumumab and Hyaluronidase for the Treatment of Multiple MyelomaJune 2021May 2025Abandon4721NoNo
17312184NOVEL POLYPEPTIDESJune 2021February 2025Abandon4401NoNo
17311537ENDOTHELIN RECEPTOR TYPE A ACTIVITY REGULATING ANTIBODYJune 2021September 2024Allow4001YesNo
17290527COMPOSITION AND METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASESApril 2021November 2024Abandon4301NoNo
17290754BISPECIFIC ANTIBODY BINDING TO CD20 AND CD3 AND USES THEREOFApril 2021April 2025Abandon4801NoNo
17288471ANTI-HUMAN CD89 ANTIBODIES AND USES THEREOFApril 2021September 2024Allow4110YesNo
17287756IL4/IL13 Receptor Molecule for Veterinary UseApril 2021June 2025Allow4911YesNo
17283614EXOSOME-TARGETING BISPECIFIC ANTIBODIESApril 2021October 2024Abandon4210NoNo
17281095METHODS FOR EXPANDING T CELLS FOR THE TREATMENT OF CANCER AND RELATED MALIGNANCIESMarch 2021November 2024Abandon4310NoNo
17275911TFR-SPECIFIC BINDING MOIETIES AND TRANSCYTOSIS METHOD TO SELECT VNARS THAT CROSS CELLULAR BARRIERSMarch 2021March 2025Allow4811YesNo
17275233MR1 RESTRICTED T CELL RECEPTORS FOR CANCER IMMUNOTHERAPYMarch 2021March 2025Abandon4801NoNo
17260783COMPOSITIONS AND METHODS FOR TREATMENT OF T CELL MALIGNANCIESJanuary 2021December 2024Abandon4710NoNo
17054483METHODS AND COMPOSITIONS FOR TREATING CANCERNovember 2020October 2024Allow4721YesNo
17040472CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOFSeptember 2020March 2025Allow5411YesNo
17015662NOVEL ANTI-TROPONIN T ANTIBODIESSeptember 2020November 2024Allow5011YesNo
16967881Activating Chimeric Receptors and Uses Thereof In Natural Killer Cell ImmunotherapyAugust 2020November 2024Allow5120YesNo
16967243METHODS FOR TREATING CANCER USING COMBINATIONS OF ANTI-BTNL2 AND IMMUNE CHECKPOINT BLOCKADE AGENTSAugust 2020February 2025Allow5511YesNo
16958250METHOD FOR IMPROVING PRODUCTION OF CAR T CELLSJune 2020March 2025Allow5721YesNo
16642810B CELL RECEPTOR MODIFICATION IN B CELLSFebruary 2020October 2024Allow5630NoNo

Appeals Overview

No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.

Examiner CHASE, CAROL ANN - Prosecution Strategy Guide

Executive Summary

Examiner CHASE, CAROL ANN works in Art Unit 1646 and has examined 34 patent applications in our dataset. With an allowance rate of 52.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 45 months.

Allowance Patterns

Examiner CHASE, CAROL ANN's allowance rate of 52.9% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by CHASE, CAROL ANN receive 1.06 office actions before reaching final disposition. This places the examiner in the 14% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by CHASE, CAROL ANN is 45 months. This places the examiner in the 2% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +88.9% benefit to allowance rate for applications examined by CHASE, CAROL ANN. This interview benefit is in the 100% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 50.0% of applications are subsequently allowed. This success rate is in the 97% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 25.0% of cases where such amendments are filed. This entry rate is in the 25% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Petition Practice

When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • RCEs are effective: This examiner has a high allowance rate after RCE compared to others. If you receive a final rejection and have substantive amendments or arguments, an RCE is likely to be successful.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.